Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company specializing in RNAi therapeutics, has announced the formation of a joint venture named Sagesse Bio, Inc. with US investment firm Gore Range Capital. This strategic partnership is complemented by a patent transfer and license agreement that will see Sirnaomics transferring specific intellectual property rights to SagesseBio and granting exclusive global rights and licenses for defined applications.
Sagesse Bio is poised to become a global leader in medical aesthetics, leveraging innovative technologies and aesthetic products. The agreement involves the transfer of key patents from Sirnaomics to SagesseBio, including a US patent for RNAi therapy-induced adipose tissue remodeling (US2023/0365969), a Chinese patent for nucleic acid preparation in adipose tissue reshaping (CN116350650A), and an EU patent with a similar scope (WO2023092142A8). Additionally, the license includes a US patent for a combination therapy involving TGF β and COX-2 inhibitors (US9642873) and a patent for a drug combination to activate apoptosis in human fibroblasts and myofibroblasts (US11697813).
As part of the transaction, SagesseBio will make a milestone payment of up to USD 33 million to Sirnaomics. Concurrently, Sirnaomics will acquire 2.4 million non-voting shares in SagesseBio, representing a 60% stake in the JV. Post-subscription, SagesseBio’s financial performance, assets, and liabilities will be kept separate from Sirnaomics’ group accounts, indicating a distinct operational strategy for the new entity.- Flcube.com